Nov 3 (Reuters) - Sarepta (SRPT.O), opens new tab said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not meet the main goal, sending its ...

(Reuters) -Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not meet the main goal, sending its shares plummeting over 37% in ...

PYC Therapeutics Limited ((AU:PYC)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...

To investigate how FOXP3 dE2 affects tumor immune responses, Li and colleagues examined data from patients with triple-negative breast cancer in The Cancer Genome Atlas (TCGA) and analyzed survival ...

The announcement included updates on Elevidys’ label changes for Duchenne muscular dystrophy treatment. Credit: luchschenF/Shutterstock.com. Sarepta Therapeutics is set to cut 500 jobs as part of its ...

Inositol 1,4,5-trisphosphate 3-kinase A (Itpka) is a neuronal isoform of the ITPK family that regulates both actin dynamics and calcium signaling. While itpka deficiency in adult mice mainly results ...

Phosphorodiamidate morpholino oligomers (PMOs) are synthetic DNA analogs that have become useful in treating different infectious diseases. To better characterize PNOs, Sarapeta Therapeutics personnel ...

Entrada’s trial aims to evaluate the tolerability, effectiveness and safety of the therapy. Credit: MacroEcon/Shutterstock. Entrada Therapeutics has secured authorisation from the UK Medicines and ...

Capricor Therapeutics, Inc.'s Deramiocel received FDA Priority Review with a PDUFA target date of August 31, 2025, for the treatment of patients with DMD Cardiomyopathy. Deramiocel could become the ...